About Seaport Therapeutics
Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company leverages its proprietary Glyph™ lymphatic-targeting prodrug technology platform to advance clinically validated mechanisms by enhancing oral bioavailability, bypassing first-pass metabolism, and reducing side effects such as hepatotoxicity.
Company details
Funding
Total raised
$325M
Last stage
Series B
Investors
Founders
Daphne Zohar
Founder, CEO and Board Member of Seaport Therapeutics. Previously Founder and CEO of PureTech Health, where she also co-founded Karuna Therapeutics, which developed Cobenfy (KarXT) — acquired by Bristol Myers Squibb for $14 billion.
LinkedInMichael Chen
Co-founder and CSO of Seaport Therapeutics. Previously Head of Innovation at PureTech Health, where he oversaw the neuropsychiatric medicines that led to Seaport's launch. Also Co-founder and Head of Research and Strategy at Sonde Health.
Steven M. Paul
Founder and Board Chair at Seaport Therapeutics. Former CEO and Chair of Karuna Therapeutics and former President of Research and Development at Eli Lilly. Over 40 years of experience as a physician-scientist in neuroscience and CNS drug discovery.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.